Prof. Capdevila shares his views on the potential impact of ongoing phase III studies on the guidelines for managing well-differentiated neuroendocrine tumors.

Discover how the recent advancements in theranostics have revolutionized nuclear medicine through Prof. Pubul Núñez's insightful explanation.

Professor Nagarajah guides us through the latest developments in PSMA-targeting radiopharmaceuticals and shares his views on the role of dosimetry in radionuclide therapy.